(Q35825361)

10 August 2017

A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics (English)

1 reference

10 August 2017

0 references

Stephen J Fowler

4

0 references

author name string

Graeme P Currie

1

1 reference

10 August 2017

Daniel K C Lee

2

1 reference

10 August 2017

Owen J Dempsey

3

1 reference

10 August 2017

Louise M Cowan

5

1 reference

10 August 2017

Brian J Lipworth

6

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

British Journal of Clinical Pharmacology

10 August 2017

1 reference

10 August 2017

55

1 reference

10 August 2017

6

1 reference

10 August 2017

609-615

1 reference

Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Leukotriene-receptor antagonists

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and the method of assessing response

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Standardization of Spirometry, 1994 Update. American Thoracic Society

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

27 July 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01813.X

Bronchial responsiveness to adenosine 5'-monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV(1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01813.X

The effect of salmeterol on markers of airway inflammation following segmental allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01813.X

Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Leukotriene antagonists and symptom control in chronic persistent asthma

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884256

Greater effect of inhaled budesonide on adenosine 5'-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma

24 September 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01813.X

Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2125.2003.01813.X

The long‐acting β2‐agonist salmeterol xinafoate: effects on airway inflammation in asthma

21 January 2018

1 reference

12 December 2020

Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids

1 reference

12 December 2020

Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma

1 reference

12 December 2020

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

12 December 2020

10.1046/J.1365-2125.2003.01813.X

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

12814457

1 reference